Key Highlights

  • SALT‑20, SALT‑30 and SALT‑50 response thresholds correspond to 80%, 30% and 50% scalp hair coverage improvements, respectively.
  • Q32 Bio (NASDAQ: QTTB) announced top‑line data from the second segment of its SIGNAL‑AA Phase 2a study, evaluating the experimental therapy bempikibart in adults with severe alopecia areata.
  • The open‑label Part B extension enrolled 33 participants with baseline Severity of Alopecia Tool (SALT) scores ranging from 50 to 100.

Q32 Bio (NASDAQ: QTTB) announced top‑line data from the second segment of its SIGNAL‑AA Phase 2a study, evaluating the experimental therapy bempikibart in adults with severe alopecia areata.

Trial Design Summary

The open‑label Part B extension enrolled 33 participants with baseline Severity of Alopecia Tool (SALT) scores ranging from 50 to 100. The study retains the primary endpoint of mean percentage change in SALT scores among the modified intent‑to‑treat population. Enrollment surpassed the original target, driven by strong patient interest.

The cohort includes individuals with disease duration up to four years.

Dosing Regimen Details

The protocol began with a loading phase of 200 mg weekly for four doses, then shifted to 200 mg every other week for the remaining 32 weeks. This schedule was designed to accelerate steady‑state drug levels, an objective confirmed by pharmacokinetic observations. These reactions were mainly solitary occurrences, with an overall incidence of 4% across all dosing events.

All injection‑site events were mild, resolved without intervention, and none progressed to serious or Grade 3 severity.

Pharmacokinetics and Immunogenicity

Bempikibart demonstrated favorable exposure patterns, reaching steady state roughly ten weeks earlier than in the earlier Part A cohort. Anti‑drug antibody formation was negligible, indicating low immunogenic risk throughout the trial duration.

Forward Strategy and Funding Status

Q32 Bio plans to initiate a registration‑focused development program in the first half of 2027, with comprehensive data from Part B to be disclosed at an upcoming medical conference.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.